Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) EBITDA (2022 - 2025)

Historic EBITDA for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to -$43.9 million.

  • Entrada Therapeutics' EBITDA fell 24492.97% to -$43.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.8 million, marking a year-over-year decrease of 28399.12%. This contributed to the annual value of $65.4 million for FY2024, which is 157502.82% up from last year.
  • Per Entrada Therapeutics' latest filing, its EBITDA stood at -$43.9 million for Q3 2025, which was down 24492.97% from -$43.1 million recorded in Q2 2025.
  • Entrada Therapeutics' EBITDA's 5-year high stood at $54.9 million during Q2 2024, with a 5-year trough of -$43.9 million in Q3 2025.
  • Moreover, its 4-year median value for EBITDA was -$16.9 million (2025), whereas its average is -$9.3 million.
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 53839.13% in 2024, then crashed by 24492.97% in 2025.
  • Entrada Therapeutics' EBITDA (Quarter) stood at -$23.9 million in 2022, then surged by 63.02% to -$8.9 million in 2023, then soared by 101.31% to $116000.0 in 2024, then tumbled by 37956.03% to -$43.9 million in 2025.
  • Its last three reported values are -$43.9 million in Q3 2025, -$43.1 million for Q2 2025, and -$16.9 million during Q1 2025.